NEWTOWN,
Pa., July 28, 2024 /PRNewswire/
-- Edelson Lechtzin LLP is investigating potential
violations of the federal securities laws involving Dexcom,
Inc. (NASDAQ: DXCM) resulting from allegations of providing
potentially misleading business information to the investing
public.
If you have non-public information that could assist in the
Dexcom Investigation or if you are a Dexcom investor who suffered a
loss and would like to learn more, you can provide your
information HERE.
You can also call attorneys Eric
Lechtzin or Marc Edelson of
Edelson Lechtzin LLP at 844-563-5550 or via e-mail at
elechtzin@edelson-law.com.
THE ALLEGED WRONGDOING
Dexcom is a manufacturer of sensors for continuous glucose
monitors ("CGMs"). On July 25, 2024,
after the market closed, Dexcom released its Q2 2024 financial
results revealing revenue of $1.004
billion. Dexcom's earnings release acknowledged that its
performance had fallen short of expectations. Dexcom also slashed
its full-year 2024 revenue guidance to a range of $4 billion to $4.05
billion, versus its previously announced guidance of
$4.20 billion to $4.35 billion, citing "certain unique items
impacting 2024 seasonality," as negatively affecting revenue.
THE REVELATION: On this news, the price of Dexcom
stock plummeted $43.85 per share, or
40%, on July 26, 2024, marking the
largest single-day drop in the company's history. In the wake of
these disappointing results, CEO Kevin
Sayer blamed a restructuring of the company's sales team,
fewer than expected new customers, and lower revenue per user.
Skeptical market analysts questioned the company's explanation and
downgraded their ratings on DXCM stock.
ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a
national class action law firm with offices in Pennsylvania and California. In addition to cases involving
securities and investment fraud, our lawyers focus on
class and collective litigation in cases alleging violations of the
federal antitrust laws, employee benefit plans under ERISA, wage
theft and unpaid overtime, consumer fraud, and
dangerous and defective drugs and medical devices.
This press release may be considered Attorney Advertising in
some jurisdictions. No class has been certified in this case, so
you are not represented by counsel unless you retain one. You may
select counsel of your choice. You may also remain an absent class
member and do nothing. Your ability to share in any potential
future recovery does not depend upon serving as lead plaintiff.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/edelson-lechtzin-llp-announces-investigation-dexcom-inc-nasdaq-dxcm-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302208164.html
SOURCE Edelson Lechtzin LLP